A randomised controlled trial comparing three methods of teaching home spirometry in adult patients with respiratory symptoms

Not Applicable

• Conditions: Respiratory disease; Respiratory

• Registration Number: ISRCTN18299685
• Lead Sponsor: orth Bristol NHS Trust

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-05-18
• Last Update Posted: 29 May 2023
• Study Completion: 2023-06-01

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 106

Inclusion Criteria

1. Require spirometry as part of their routine clinical care
2. The participant has the required technology (smartphone or tablet and an internet connection) to enable the use of the home spirometry device
3. Able to give informed consent

Exclusion Criteria

1. Age <18 years
2. Spirometry contraindicated

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Accuracy and acceptability of measurements produced by remote teaching of home spirometry (MIR Spirobank smartmeter) compared to face-to-face teaching and in-hospital spirometry (the gold standard). One or more home spirometry measurements of Forced Expiratory Volume in 1 second (FEV1), Forced Vital Capacity (FVC), FEV1/FVC and Peak Expiratory Flow Rate (PEFR) and forced expiratory flow (FEF) will be compared between each randomised group and hospital spirometry. Home spirometry recordings are submitted within 6 weeks of hospital spirometry.

Secondary Outcome Measures

Name	Time	Method
1. Feasibility of bronchodilator reversibility performed at home, assessed using home spirometry measurements of FEV1, FVC, PEFR and FEF with subsequent measurements after a short-acting bronchodilator and hospital spirometry. Home spirometry recordings are submitted within 6 weeks of hospital spirometry.<br>2. Patient acceptability of performing home spirometry, assessed by qualitative analysis of feedback questionnaires following the completion of home and hospital spirometry<br>3. Factors that affect patient willingness, adherence and quality of home spirometry, assessed by qualitative analysis of feedback questionnaires following completion of home and hospital spirometry<br>4. Disease-specific effects in ILD and airway disease patients assessed using home and hospital spirometry measurements of FEV1, FVC, PEFR and FEF spirometry. Home spirometry recordings are submitted within 6 weeks of hospital spirometry